首页> 外文期刊>Leukemia Research and Treatment >Myeloid Sarcoma: Clinicopathologic, Cytogenetic, and Outcome Analysis of 21 Adult Patients
【24h】

Myeloid Sarcoma: Clinicopathologic, Cytogenetic, and Outcome Analysis of 21 Adult Patients

机译:髓样肉瘤:21例成人患者的临床病理,细胞遗传学和结果分析

获取原文
       

摘要

Myeloid sarcoma (MS) is a neoplasm of immature granulocytes, monocytes, or both involving any extramedullary site. Twenty one patients with MS at diagnosis who were treated at King Hussein Cancer Center in Jordan were included in this retrospective study with a male to female ratio of 2 : 1. The most common site was the reticuloendothelial system. The most common morphology subtype was M2 (38%) and the most frequent chromosomal abnormality was trisomy 8. Twenty patients received induction chemotherapy; only 14 (70%) achieved complete remission. Median survival time was 24.7 months for the whole group and 58.6 months for patients who underwent allogenic bone marrow transplant. This paper showed that MS has frequent M2 morphology, carries chromosomal aberrations other than t(8;21), and requires aggressive therapy as a front line approach.
机译:髓样肉瘤(MS)是涉及任何髓外部位的未成熟粒细胞,单核细胞或两者的肿瘤。这项回顾性研究纳入了在约旦国王侯赛因癌症中心接受治疗的21名确诊为MS的患者,男女之比为2:1,最常见的部位是网状内皮系统。最常见的形态学亚型是M2(38%),最常见的染色体异常是三体性8号。20例患者接受了诱导化疗。只有14个(70%)完全缓解。整个组的中位生存时间为24.7个月,接受同种异体骨髓移植的患者中位生存时间为58.6个月。本文显示MS具有频繁的M2形态,携带t(8; 21)以外的染色体畸变,并且需要积极治疗作为前线治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号